SCHEMBL17532913

SCHEMBL17532913

Cc1ccc(-c2ccc(-c3cc(-c4ccc(-c5ccc(C)cn5)cc4)cc(-c4nc(-c5ccccc5)nc(-c5ccccc5)n4)c3)cc2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.48
KMT2A Q03164 7/20 0.48
CYP3A4 P08684 3/20 0.47
CYP2A6 P11509 1/20 0.47
ALDH1A1 P00352 3/20 0.46
MAPT P10636 3/20 0.46
HPGD P15428 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.44
CCR1 P32246 1/20 0.44
CCR5 P51681 1/20 0.44
CCR8 P51685 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
KDM4E B2RXH2 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
PDGFRB P09619 1/20 0.43
KDR P35968 1/20 0.43
FLT3 P36888 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21729301 0.94 CYP3A4 (0.47) MEN1KMT2ACYP3A4CYP2A6ALDH1A1
SCHEMBL10057488 0.94 CYP3A4 (0.53) MEN1KMT2ACYP3A4CYP2A6ALDH1A1
SCHEMBL21202993 0.93 MEN1 (0.50) MEN1KMT2ACYP3A4ALDH1A1MAPT
SCHEMBL18325206 0.93 MEN1 (0.50) MEN1KMT2ACYP3A4ALDH1A1MAPT
SCHEMBL18325353 0.93 MEN1 (0.50) MEN1KMT2ACYP3A4ALDH1A1MAPT
SCHEMBL18325208 0.90 MEN1 (0.47) MEN1KMT2ACYP3A4CYP2A6ALDH1A1
SCHEMBL18325355 0.90 MEN1 (0.47) MEN1KMT2ACYP3A4CYP2A6ALDH1A1
SCHEMBL19037228 0.89 CCR1 (0.52) MEN1KMT2ACYP3A4CYP2A6ALDH1A1
SCHEMBL18325364 0.88 MEN1 (0.51) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL18325243 0.88 MEN1 (0.51) MEN1KMT2AALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 US disclosed
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 US disclosed
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION TOSOH CORPORATION (JP) 2016-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160056388-A1 HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION AOC2, AZI2, KCNH2 MEN1 2195/4885KMT2A 1481/4885CYP3A4 1069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.